苑东生物 (688513.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

18.9x

Market Cap

CNY 7.58B

MomentumView details →

1D Return

−5.82%

YTD Return

—

RSI (14)

44.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

18.9x

Market Cap

CNY 7.58B

RSI (14)

44.3

MomentumView details →

1D Return

−5.82%

YTD Return

—

ProfitabilityView details →

Gross Margin

74.89%

Net Margin

20.29%

EBITDA Margin

30.23%

ROE (TTM)

9.18%

ROA (TTM)

7.26%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

+0.87%

EPS YoY

+22.90%

FCF YoY

+45.10%

Revenue CAGR 3Y

+4.39%

EPS CAGR 3Y

−7.36%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.45

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.11%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

3.82x

Quick Ratio

3.38x

Div Yield

1.10%

Div Rate

CNY 0.49

Div Growth 1Y

+13.95%

Financials snapshotView financials →

Revenue (TTM)

1.35B

Net Income (TTM)

274.30M

Op. CF (TTM)

311.54M

Latest newsMore news →

Yuandong Biologics announced that as of the end of August 2026, it had repurchased 1,386,528 shares (0.7854% of total share capital) for a total amount of 60.7535 million yuan, within its buyback program running from June 4 to September 3, 2026.4d ago

Yuandong Biologics announced its first-half 2026 results: revenue of 659 million yuan, net profit down 4.99% year-on-year.15d ago

Similar companies

Lepu Biopharma Co., Ltd.02157.HK Alkermes plcALKS CARsgen Therapeutics Holdings Limited02171.HK Belite Bio, IncBLTE Spyre Therapeutics, Inc.SYRE Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H02335.HK Find similar companies →

Latest newsMore news →

Yuandong Biologics announced that as of the end of August 2026, it had repurchased 1,386,528 shares (0.7854% of total share capital) for a total amount of 60.7535 million yuan, within its buyback program running from June 4 to September 3, 2026.4d ago Yuandong Biologics announced its first-half 2026 results: revenue of 659 million yuan, net profit down 4.99% year-on-year.15d ago